Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas.
The appointment of a dedicated executive to lead the Company’s long-term strategy in the Americas is indicative of the growing regional demand trends and the Company’s commitment to broaden its footprint, accelerate its market penetration and improve proximity to its customers in this important region.
“We are excited to welcome Riccardo Butta to Stevanato Group”, said Franco Moro, CEO of Stevanato Group. “We believe the Americas represent a significant growth opportunity for our company, and we are confident that Riccardo’s deep commercial, operational and management expertise will help us strengthen our presence and advance our strategic priorities in this important region.”
Riccardo Butta, President, Americas, commented: “I look forward to working with this talented leadership team to expand our presence and market share in the Americas, while continuing Stevanato Group’s mission to serve its customers through an integrated approach, from design and development through to commercialization.”
Riccardo Butta joins the Group with more than 30 years of management experience, including 20 years with Flex Ltd., an industry-leading contract development and manufacturing organization with operations spanning 30 countries, including a large presence in the U.S. and Mexico. In his most recent role as Senior Vice President, Riccardo was responsible for the global commercial organization of Flex Health Solutions, a business unit of Flex providing contract design, manufacturing, and logistics services to the healthcare industry with a focus on medical devices, drug delivery solutions, and medical/life sciences equipment. During his tenure at Flex, Riccardo was also responsible for the European organization of Flex Health Solutions, for the global engineering organization focused on medical device development, and for scaling up the Milan medical design center.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients.
02.02.2022, Stevanato
此网站新闻材料的版权属于公司或第三方的新闻提供者，其所有权利保留。所有新闻材料对其访问者只能限于其本人使用，并且使用此材料的风险由其使用者独自自行承担。严禁对新闻材料进行再次发布和其它商业利用. 作为商业贸易的用途。如果新闻材料由第三方提供，当应用此新闻材料时，每个使用者都同意遵守，并且受此特定的项目的约束。Glass Global并不代表及认可新闻材料中所包含的内容及新闻中的外部网站的内容的准确性及可靠性。
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.